For now, Eli Lilly's orforglipron appears to be the top contender in the weight loss pill space due to its strong efficacy data and ease of use.
None of the three drugmakers have provided estimates for how much the new obesity pills would cost.
Eli Lilly's results appear consistent with the weight reduction caused by Novo Nordisk's pill, but were achieved over a shorter trial period.average weight loss of 15.1%Bank of America analyst Geoff Meacham said in a Sunday research note that Eli Lilly's available orforglipron data "compares quite favorably" to Novo Nordisk's oral semaglutide, "cross trial comparison caveats aside.
At least for now, analysts say Eli Lilly's pill may also have the upper hand over Pfizer's oral GLP-1,Patients with Type 2 diabetes who took a 120-milligram version of danuglipron twice a dayon average after 16 weeks, according to results from one phase two clinical trial. Health experts seem to agree: "Patient compliance increases a lot if it's a once-a-day pill, so it's definitely a big advantage. People often end up missing a few times a week if they have to take something twice a day," saidPfizer is developing a once-daily version of danuglipron.another experimental pill, lotiglipron, which Bansal said had been the "more attractive GLP-1" in Pfizer's portfolio since it's only taken once a day.
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Eli Lilly Experimental Obesity Drug Could Beat Rivals in Total Weight Loss for PatientsObese or overweight patients who took Eli Lilly’s retatrutide lost 58 pounds on average, the pharmaceutical company said in a mid-stage clinical trial.
Weiterlesen »
Next-generation drug from Eli Lilly boosts weight loss to 24%, highest yet seen in trialsIn addition to the 24% average weight loss on the highest dose in the trial – about 58 pounds over 11 months – a quarter of patients on that dose experienced weight loss of at least 30%.
Weiterlesen »
Breakingviews - Eli Lilly gorges on obesity optionsEli Lilly has filled its plate with potential obesity treatments, unveiling data from two more on Monday. One offers the convenience of a pill; the other, with the scientific name retatrutide, led to patients losing an astonishing 24% of their weight at the highest dose.
Weiterlesen »
Eli Lilly's weight loss drugs trounce sky-high expectations, boosting the stockThe weight loss medication market is shaping up to be a duopoly of Eli Lilly and Novo Nordisk, analysts said.
Weiterlesen »
Daily pill from Eli Lilly leads to 15% weight loss in midstage study, rivaling Wegovy results without the shotEli Lilly’s experimental pill for weight loss helped people lose an average of 15% of their body weight after 36 weeks on the highest dose in a midstage trial.
Weiterlesen »
Experimental drug could offer more weight loss than any drug now on the market, study findsThe experimental drug, retatrutide, helped people lose, on average, about 24% of their body weight, the equivalent of about 58 pounds, in a mid-stage clinical trial, the company says.
Weiterlesen »